Mraz Amerine & Associates Inc. held its stake in shares of Merck & Company, Inc. (NYSE:MRK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,869 shares of the company’s stock at the close of the 2nd quarter. Mraz Amerine & Associates Inc.’s holdings in Merck & were worth $312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. IBM Retirement Fund grew its position in Merck & by 70.8% in the second quarter. IBM Retirement Fund now owns 67,037 shares of the company’s stock worth $4,801,000 after acquiring an additional 27,798 shares in the last quarter. NGAM Advisors L.P. increased its stake in Merck & by 2.5% during the second quarter. NGAM Advisors L.P. now owns 937,470 shares of the company’s stock worth $60,083,000 after acquiring an additional 22,659 shares during the last quarter. Greystone Managed Investments Inc. increased its stake in Merck & by 13.2% during the second quarter. Greystone Managed Investments Inc. now owns 169,236 shares of the company’s stock worth $10,846,000 after acquiring an additional 19,769 shares during the last quarter. Arthur M. Cohen & Associates LLC increased its stake in Merck & by 4.2% during the second quarter. Arthur M. Cohen & Associates LLC now owns 46,896 shares of the company’s stock worth $2,923,000 after acquiring an additional 1,908 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its stake in Merck & by 3.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 133,070 shares of the company’s stock worth $8,528,000 after acquiring an additional 3,830 shares during the last quarter. Institutional investors own 72.92% of the company’s stock.

MRK has been the subject of several analyst reports. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating and set a $70.00 target price on shares of Merck & in a research report on Friday, September 1st. Credit Suisse Group restated a “buy” rating on shares of Merck & in a report on Tuesday, June 13th. Jefferies Group LLC restated a “sell” rating and set a $52.00 price target on shares of Merck & in a report on Sunday, August 20th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $74.00 price target (up previously from $70.00) on shares of Merck & in a report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $70.00.

Shares of Merck & Company, Inc. (NYSE MRK) opened at 64.55 on Tuesday. The firm’s 50-day moving average price is $64.03 and its 200-day moving average price is $63.66. The company has a market capitalization of $176.05 billion, a price-to-earnings ratio of 34.95 and a beta of 0.80. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The firm had revenue of $9.93 billion during the quarter, compared to the consensus estimate of $9.75 billion. During the same quarter last year, the firm earned $0.93 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Equities research analysts expect that Merck & Company, Inc. will post $3.87 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is 76.11%.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/mraz-amerine-associates-inc-has-312000-stake-in-merck-company-inc-mrk/1604351.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.